Search clinical trials for: CKD-379(Empagliflozin sitagliptin metformin) Reference drug

Total 443 results

Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

Type 2 Diabetes Mellitus

Korea, Republic of
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers

Chronic Renal Failure

Korea, Republic of
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389

Type 2 Diabetes

Korea, Republic of
University of Pisa

Unknown

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. (UTI-flog)

Type 2 Diabetes | Urinary Tract Infections

Italy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378

Type II Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety Profile of CKD-333

Hypertension | Dyslipidemias

Korea, Republic of
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
EMS

Not yet recruiting

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Type 2 Diabetes Mellitus
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers

Cardiovascular Diseases

Korea, Republic of
Korea University Anam Hospital
AstraZeneca

Unknown

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Diabetes Mellitus, Type II

Korea, Republic of
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator

Healthy Subjects
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Healthy

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
University Medical Centre Ljubljana

Unknown

The Effects of Empagliflozin on Arterial Wall Characteristics

Diabetes Complications | Diabetes Mellitus, Type 1 | Vascular Stiffness | Hypoglycemic Agents

Slovenia
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845

Hypogonadism

Korea, Republic of
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
University of Diyala

Completed

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Type 2 Diabetes

Iraq
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Healthy

Germany
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes (4T)

Insulin Resistance | Prediabetic State

Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)

Cardiovascular Diseases

Korea, Republic of
Chong Kun Dang Pharmaceutical

Recruiting

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers

Anticoagulant

Korea, Republic of
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

Anticoagulant

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)

Cardiovascular Diseases

Korea, Republic of
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Healthy Subjects
Chong Kun Dang Pharmaceutical
Seoul National University Bundang Hospital

Completed

Compare the Pharmacokinetics and Safety of CKD-391

Hyperlipidemias

Korea, Republic of
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
Chong Kun Dang Pharmaceutical

Completed

Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers

Diabetes Mellitus, Type II

Korea, Republic of
George Medicines PTY Limited
The George Institute; Brandon Biocatalyst

Not yet recruiting

Polypill Versus Metformin in New Onset Type 2 Diabetes (PiVOT)

Type 2 Diabetes
Alexandria University

Recruiting

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS)

Egypt
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions

Cardiovascular Diseases

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Rheumatoid Arthritis

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus

3

Subscribe